Breathe Well Live Well
|
Low asthma medication adherence predictors identified in adolescents
medwireNews medwireNews: Inhaled corticosteroid (ICS) adherence among adolescents with asthma is low and is associated with a lack of knowledge about treatment and patients' perceptions about their medicines, show findings of a study published in the Journal of … |
View full post on asthma – Google News
Condition: Oral Corticosteroid Dependent Asthma
Interventions: Biological: Tralokinumab; Other: Placebo
Sponsor: AstraZeneca
Not yet recruiting – verified October 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: budesonide/formoterol ‘as needed’ + budesonide placebo bid; Drug: budesonode bid + terbutaline ‘as needed’
Sponsor: AstraZeneca
Not yet recruiting – verified August 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Uncontrolled Asthma
Interventions: Biological: Tralokinumab; Biological: Placebo
Sponsor: AstraZeneca
Not yet recruiting – verified July 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Conditions: Asthma; Tobacco; Waterpipe; Cigarettes
Intervention: Behavioral: TAJ Plus (Adolescent Asthma Action in Jordan) Plus the added class smoke free pledge
Sponsors: University of Technology, Sydney; University of Technology, Sydney; Jordan University of Science and Technology
Completed – verified September 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Top Resources for Children, Adolescents, and Their Families
Medscape Asthma is the most common chronic respiratory condition in children. The Centers for Disease Control and Prevention (CDC, 2011) reported that asthma affected 7.1 million children, with 4.1 million experiencing an asthma attack. The primary goal of … |
View full post on asthma – Google News
| Related Articles |
Guideline-Recommended Fractional Exhaled Nitric Oxide is a Poor Predictor of Health Care Use Among Inner-city Children and Adolescents Receiving Usual Asthma Care.
Chest. 2013 Jun 13;
Authors: McCormack MC, Aloe C, Curtin-Brosnan J, Diette GB, Breysse PN, Matsui EC
Abstract
ABSTRACT BACKGROUND: Recent American Thoracic Society (ATS) guidelines support use of FENO in patients with asthma and highlight gaps in the evidence base. Little is known about use of FENO to predict asthma exacerbations among high-risk, urban, minority populations receiving usual care. METHODS: 138 children with persistent asthma were enrolled in a prospective observational cohort study and skin tested at baseline (wheal?3mm=+SPT). Fractional exhaled nitric oxide (FENO) levels, lung function, and asthma-related health care use were assessed at baseline and every three months thereafter for one year. Relationships between FENO and health care utilization in the subsequent three months were examined. Final models accounted for repeated outcome measures and were adjusted for age, gender and lung function. RESULTS: The mean age was 11 years (range 5-17), and most were male (57%), African American (91%), and atopic (90%). At baseline, FENO was (median [IQR]: 31.5ppb [16-61]) and FEV1/FVC was (mean ± SD: 80.7±9.6%). There were 237 acute asthma-related health care visits, 105 unscheduled doctor (UD) visits, 125 ED visits, and 7 hospitalizations during the follow-up period. FENO was not a significant predictor of acute visits, ED visits, UD visits, or hospitalization in either unadjusted or adjusted analyses. Use of recommended cutpoints did not improve the predictive value of FENO (PPV 0.6-32.8%), nor did application of the guideline-based algorithm to assess change over time. CONCLUSIONS: FENO may not be a clinically useful predictor of health care use for asthma exacerbations in urban minority children with asthma.
PMID: 23764806 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
| Related Articles |
Differences in Health Care Access and Utilization Between Adolescents and Young Adults With Asthma.
Pediatrics. 2013 Apr 22;
Authors: Chua KP, Schuster MA, McWilliams JM
Abstract
OBJECTIVE:Studies suggest that young adults have worse health care access, use less primary care, and visit emergency departments more frequently than adolescents. We examined whether these differences existed between older adolescents and young adults with asthma.METHODS:Using nationally representative data from the 1999 to 2009 Medical Expenditure Panel Survey, we performed cross-sectional comparisons of access and utilization between older adolescents (ages 14-17) and young adults (ages 19-25) with asthma. In longitudinal analyses, we assessed whether changes in health insurance coverage, schooling, and adult presence at home predicted changes in access and utilization.RESULTS:Young adults with asthma were less likely to have a usual source of care (-13.7 percentage points; P < .001) or primary care visit within the past year (-13.9 percentage points; P = .006). They were less likely to fill a short-acting beta-agonist prescription (-10.6 percentage points; P = .02) and more likely to visit the emergency department within the past year (+9.7 percentage points; P = .01). Adjusting for differences in insurance coverage reduced differences in usual source of care and primary care use by 32.4% to 38.0% but reduced the difference in emergency department use by only 10.3%. Among participants aged 16 to 19 in the first survey year, becoming uninsured strongly predicted losing a usual source of care (change relative to no coverage loss: -25.2 percentage points; P = .003).CONCLUSIONS:Compared with older adolescents with asthma, young adults with asthma have worse health care access and may use care less optimally. These differences were associated with but were not completely explained by differences in insurance coverage.
PMID: 23610211 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
|
Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with …
PR Newswire (press release) Boehringer Ingelheim announced that a comprehensive confirmatory Phase III trial program named UniTinA-asthma™ is ongoing to fully evaluate the potential of the long-acting bronchodilator in the treatment of asthma in pediatric, adolescent and adult … Promising Phase II Data With Once-Daily Tiotropium may Lead to New Treatment … Results of Phase II Study of Boehringer Ingelheim's Investigational … |
View full post on asthma – Google News
|
Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with …
MarketWatch (press release) Boehringer Ingelheim announced that a comprehensive confirmatory Phase III trial program named UniTinA-asthma(TM) is ongoing to fully evaluate the potential of the long-acting bronchodilator in the treatment of asthma in pediatric, adolescent and adult … Boehringer Ingelheim Announces Positive Phase II Results for Once-Daily … Results of Phase II Study of Boehringer Ingelheim's Investigational … |
View full post on asthma – Google News